Blockade of tumour necrosis factor α significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 64, Issue 8, 2005, Pages 1224-1226

  Yazdani Biuki, B ^a   Stadlmaier, E ^a   Mulabecirovic, A ^a   Brezinschek, R ^a   Tilz, G ^a   Demel, U ^a   Mueller, T ^a   Brickmann, K ^a   Graninger, W B ^a   Brezinschek, H P ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DNA ANTIBODY; ETANERCEPT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NUCLEOSOME ANTIBODY; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 23444432319     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.030262     Document Type: Article

References (14)

1. Janossy G, Panayi G, Duke O, Bofill M, Poulter LW, Goldstein G. Rheumatoi arthritis: a disease of T-lymphocyte/immunoregulation. Lancet 1981;ii:839-42.
2. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79.
3. Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003;62:427-30.
4. Teitsson I, Valdimarsson H. Use of monoclonal antibodies and F(ab′)2 enzyme conjugates in ELISA for IgM, IgA and IgG rheumatoid factors. J Immunol Methods 1984;71:149-61.
5. Moreland LW, Bucy RP, Weinblatt ME, Mohler KM, Spencer-Green GT, Chatham WW. Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol 2002;103:13-21.
6. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002;359:579-80.
7. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43:2383-90.
8. Bickston SJ, Lichtenstein GR, Arseneau KO, Cohen RB, Cominelli F. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology 1999;117:1433-7.
9. Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 2004;16:254-61.
10. Edwards JC, Cambridge G, Abrahams VM. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology 1999;97:188-96.
11. Fu YX, Molina H, Matsumoto M, Huang G, Min J, Chaplin DD. Lymphotoxin-alpha (LTalpha) supports development of splenic follicular structure that is required for IgG responses. J Exp Med 1997;185:2111-20.
12. Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF-alpha therapy. Ann Rheum Dis 2005;64:403-7.
13. Wascher TC, Hermann J, Brezinschek HP, Brezinschek R, Wilders-Truschnig M, Rainer F, et al. Cell-type specific response of peripheral blood lymphocytes to methotrexate in the treatment of rheumatoid arthritis. Clin Investig 1994;72:535-40.
14. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial, Lancet 2004;363:675-81.